Cost-Effectiveness of Linezolid vs Vancomycin in Suspected Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia in Germany

Abstract

The model estimated a higher clinical cure (+8.7%) and survival (+13.2%) for linezolid compared with vancomycin at an incremental cost of <euro>420 per treatment episode. The cost-benefit profile suggests that linezolid could be considered a cost-effective alternative to vancomycin in the treatment of patients with NP caused by suspected MRSA in Germany.

The use of bone cement for the localized, controlled release of the antibiotics vancomycin, linezolid, or fusidic acid: effect of additives on drug release rates and mechanical strength

“…Since linezolid has a similar MIC to vancomycin for resistant bacteria (approximately 0.25-0.5 ug/ml [9,32]) it is likely that these release profiles will provide above MIC levels of linezolid at treatment sites. Since linezolid is almost four times as expensive as vancomycin [11] and the sustained release of large amounts of the drug is particularly important to prevent the development of resistance, these data support the inclusion of excipients like salt in linezolid-loaded cement.…”

Linezolid vs Glycopeptide Antibiotics for the Treatment of Suspected Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia

“…35 Multiple studies have investigated the costeffectiveness of linezolid for MRSA pneumonia, [36][37][38][39] using pooled data from Rubinstein et al 22 and Wunderink et al 23 These studies conclude that, despite linezolid costs approximately 10 times that the Panton-Valentine Leukocidin (PVL) toxin associated with necrotizing pneumonias, 32,33 is the mechanism of putative superiority for linezolid. Importantly, the studies included in our meta-analysis focused on nosocomial MRSA pathogens, which are less likely to produce the PVL toxin, as compared with emerging community-acquired MRSA.…”

Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis

“…Previous economic studies have demonstrated that linezolid is more cost-effective than vancomycin for NP patients [33][34][35][36]; the clinical data used in those studies were from Rubinstein et al [24] and Wunderink et al [26]. However, Walkey et al [14] questioned the use of pooled data.…”